Here’s their press launch in full....NEW YORK, Jan. 26, 2021 /PRNewswire/ — atai Life Sciences (“atai” or the “Company”), a world biotech firm growing psychedelic and non-psychedelic compounds for varied psychological well being indications, in the present day introduced it has entered right into a collaboration with Massachusetts General Hospital (“MGH”) and its new initiative, the Center for Neuroscience of Psychedelics, to advance novel psychological well being therapies by way of the examine of mechanisms underlying the therapeutic results of psychedelic brokers.
“It is our privilege to partner with the MGH in collaboration with their newly established Center for Neuroscience of Psychedelics to further research the therapeutic potential of psychedelics to treat mental health disorders,” mentioned Srinivas Rao, CSO & Co-Founder of atai. “Together, we can accelerate the study of mechanisms leveraging the MGH’s state-of-the-art approaches, tools and some of the greatest minds in neuroscience. This collaboration may lead to the discovery of novel mechanisms of neuroplasticity and development of more targeted treatments for mental illnesses, thereby pioneering the new frontier of precision mental health.”
Universally acknowledged as a number one educational medical middle, the MGH is the unique and largest instructing hospital of Harvard Medical School. The MGH not too long ago established its Center for Neuroscience of Psychedelics to higher perceive how psychedelics improve the mind’s capability for change to optimize present therapies and create new therapies for psychological sickness.
The new middle integrates and leverages the experience of the MGH’s Department of Psychiatry, the Department of Radiology’s Athinoula A. Martinos Center for Biomedical Imaging, and the Center for Genomic Medicine’s Chemical Neurobiology Laboratory. The MGH Center for Neuroscience of Psychedelics is led by Jerrold F. Rosenbaum, MD, psychiatrist-in-chief emeritus, director of the Center for Anxiety and Traumatic Stress Disorders, and Stanley Cobb Professor of Psychiatry at Harvard Medical School; Bruce Rosen, MD, PhD, director of the Martinos Center and professor of Radiology at Harvard Medical School; and Stephen J. Haggarty, PhD, director of the Chemical Neurobiology Laboratory within the MGH Center for Genomic Medicine and affiliate professor of Neurology at Harvard Medical School.
“We are excited about the opportunity to evaluate compounds in atai’s pipeline that may prove to be effective in addressing unmet needs of patients with devastating psychiatric disorders,” mentioned Dr. Rosenbaum. “There is accumulating evidence that psychedelics have unique disease-modifying potential. Understanding how these medicines enhance the brain’s capacity for change could lead to much-needed novel treatments for mental illness.”
“The relationship between atai and the MGH’s Center for Neuroscience of Psychedelics is built upon our shared goals of advancing the neuroscientific underpinnings of psychedelics on the way to meaningfully improving treatments for patients in need,” mentioned Jacob Hooker, PhD, Phyllis and Jerome Lyle Rappaport MGH Research Scholar, director of Radiochemistry on the Martinos Center, and professor of Radiology at Harvard Medical School, who’s co-leading, with Dr. Haggarty, the preliminary scope of the collaboration.